Antidyslipidemic effect of a novel vanadium-3-hydroxy flavone complex in streptozotocin-induced experimental diabetes in rats

Biomedicine & Preventive Nutrition Pub Date : 2014-04-01 DOI:10.1016/j.bionut.2013.04.004

Subramanian Iyyam Pillai , Sorimuthu Pillai Subramanian , Muthusamy Kandaswamy

{"title":"Antidyslipidemic effect of a novel vanadium-3-hydroxy flavone complex in streptozotocin-induced experimental diabetes in rats","authors":"Subramanian Iyyam Pillai , Sorimuthu Pillai Subramanian , Muthusamy Kandaswamy","doi":"10.1016/j.bionut.2013.04.004","DOIUrl":null,"url":null,"abstract":"<div><p><span>Diabetic dyslipidemia<span>, defined as atherogenic dyslipidemia, is thought to be highly responsible for the increased cardiovascular complications in diabetes mellitus. It is due to hyperglycemia and dysregulation in fatty acid metabolism. Recently, we have reported the antidiabetic and antioxidant properties of a novel vanadium-3-hydroxy flavone complex in streptozotocin-induced diabetic rats. In the present study, diabetic rats were treated with vanadium-3-hydroxy flavone complex (5</span></span>  <span>days and the status of the lipid profile in the serum, liver and kidney was evaluated. The increased levels of lipid contents in serum and tissues observed in diabetic rats were reinstated to near normal levels by the administration of the vanadium-3-hydroxy flavone complex. Also the decreased levels of HDL-cholesterol and increased levels of LDL- and VLDL-cholesterol in serum of diabetic rats were normalized upon treatment with the complex. The results of the present study illustrate the antidyslipidemic property of the vanadium-3-hydroxy flavone complex. The observed antidyslipidemic property of the complex might be due to its insulin mimetic nature.</span></p></div>","PeriodicalId":100182,"journal":{"name":"Biomedicine & Preventive Nutrition","volume":"4 2","pages":"Pages 189-193"},"PeriodicalIF":0.0000,"publicationDate":"2014-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bionut.2013.04.004","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedicine & Preventive Nutrition","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2210523913000287","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 9

Abstract

Diabetic dyslipidemia, defined as atherogenic dyslipidemia, is thought to be highly responsible for the increased cardiovascular complications in diabetes mellitus. It is due to hyperglycemia and dysregulation in fatty acid metabolism. Recently, we have reported the antidiabetic and antioxidant properties of a novel vanadium-3-hydroxy flavone complex in streptozotocin-induced diabetic rats. In the present study, diabetic rats were treated with vanadium-3-hydroxy flavone complex (5 mg/kg body weight/day) for a period of 30 days and the status of the lipid profile in the serum, liver and kidney was evaluated. The increased levels of lipid contents in serum and tissues observed in diabetic rats were reinstated to near normal levels by the administration of the vanadium-3-hydroxy flavone complex. Also the decreased levels of HDL-cholesterol and increased levels of LDL- and VLDL-cholesterol in serum of diabetic rats were normalized upon treatment with the complex. The results of the present study illustrate the antidyslipidemic property of the vanadium-3-hydroxy flavone complex. The observed antidyslipidemic property of the complex might be due to its insulin mimetic nature.

查看原文本刊更多论文

新型钒-3-羟基黄酮复合物对链脲佐菌素诱导的实验性糖尿病大鼠的降血脂作用

糖尿病性血脂异常，被定义为动脉粥样硬化性血脂异常，被认为是糖尿病心血管并发症增加的主要原因。这是由于高血糖和脂肪酸代谢失调所致。最近，我们报道了一种新型钒-3-羟基黄酮复合物在链脲佐菌素诱导的糖尿病大鼠中的抗糖尿病和抗氧化性能。本研究采用3-羟基黄酮钒复合物(5 mg/kg体重/天)治疗糖尿病大鼠30 d，观察其血清、肝脏和肾脏的脂质状况。3-羟基黄酮钒配合物使糖尿病大鼠血清和组织脂质含量恢复到接近正常水平。糖尿病大鼠血清hdl -胆固醇水平降低，LDL-胆固醇和vldl -胆固醇水平升高。本研究结果说明了钒-3-羟基黄酮配合物的抗血脂异常特性。观察到的复合物的抗血脂异常特性可能是由于它的胰岛素模拟性质。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomedicine & Preventive Nutrition

自引率

0.00%

发文量